Pfizer (PFE) FCF Margin (2009 - 2026)
Pfizer (PFE) reported FCF Margin of 93.16% for Q1 2026, up 934.0% year-over-year from 9.01% in Q1 2025, and up 263.22% on a QoQ basis from 25.65% in Q4 2025.
Pfizer (PFE) has 18 years of FCF Margin data on file, last reported at 93.16% in Q1 2026.
- Quarterly FCF Margin rose 934.0% year-over-year to 93.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.76% (up 2774.0% YoY) and the FY2025 annual result came in at 14.5%, down 10275.0% from the prior year.
- FCF Margin improved to 93.16% in Q1 2026 per PFE's latest filing, from 25.65% in the prior quarter.
- Across five years, FCF Margin topped out at 911.99% in Q3 2024 and bottomed at 60.8% in Q3 2023.
- The 5-year median for FCF Margin is 26.74% (2022), against an average of 105.05%.
- The widest annual swing landed in 2024, when FCF Margin jumped 75114 bps; it then tumbled 73788 bps in 2025.
- Tracing PFE's FCF Margin over 5 years: stood at 81.5% in 2022, then surged by 50 bps to 122.19% in 2023, then soared by 646 bps to 911.99% in 2024, then sank by 97 bps to 25.65% in 2025, then jumped by 263 bps to 93.16% in 2026.
- Per Business Quant, the three latest PFE FCF Margin figures stand at 93.16% (Q1 2026), 25.65% (Q4 2025), and 174.11% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 15.19% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 6.09% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 23.76% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 17.97% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 17.14% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 34.87% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 93.16% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 6.59% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 93.16% |
| Dec 31, 2025 | 25.65% |
| Sep 28, 2025 | 174.11% |
| Jun 29, 2025 | -52.79% |
| Mar 30, 2025 | 83.81% |
| Sep 29, 2024 | 911.99% |
| Jun 30, 2024 | -18.20% |
| Mar 31, 2024 | 2.59% |
| Dec 31, 2023 | 122.19% |
| Oct 1, 2023 | 160.85% |
| Jul 2, 2023 | -60.80% |
| Apr 2, 2023 | 2.01% |
| Oct 2, 2022 | 81.50% |
| Jul 3, 2022 | 26.74% |
| Apr 3, 2022 | 22.98% |
| Oct 3, 2021 | 105.20% |
| Jul 4, 2021 | 56.94% |
| Apr 4, 2021 | 27.45% |
| Sep 27, 2020 | 48.18% |
| Jun 28, 2020 | 41.32% |
| Mar 29, 2020 | 16.92% |
| Sep 29, 2019 | 31.11% |
| Jun 30, 2019 | 16.07% |
| Mar 31, 2019 | 9.44% |
| Dec 31, 2018 | -245.97% |
| Sep 30, 2018 | 35.43% |
| Jul 1, 2018 | 25.42% |
| Apr 1, 2018 | 12.37% |
| Dec 31, 2017 | 46.62% |
| Oct 1, 2017 | 33.71% |
| Jul 2, 2017 | 21.65% |
| Apr 2, 2017 | 9.59% |
| Dec 31, 2016 | 39.27% |
| Oct 2, 2016 | 33.00% |
| Jul 3, 2016 | 24.38% |
| Apr 3, 2016 | 11.59% |
| Dec 31, 2015 | 30.52% |
| Sep 27, 2015 | 39.14% |
| Jun 28, 2015 | 32.33% |
| Mar 29, 2015 | 4.06% |
| Dec 31, 2014 | 39.98% |
| Sep 28, 2014 | 33.88% |
| Jun 29, 2014 | 29.82% |
| Mar 30, 2014 | 23.28% |
| Dec 31, 2013 | 39.14% |
| Sep 29, 2013 | 44.47% |
| Jun 30, 2013 | 26.58% |
| Mar 31, 2013 | 16.93% |
| Dec 31, 2012 | 32.06% |
| Sep 30, 2012 | 36.42% |
| Jul 1, 2012 | 26.68% |
| Apr 1, 2012 | 16.93% |
| Dec 31, 2011 | 39.13% |
| Oct 2, 2011 | 23.99% |
| Jul 3, 2011 | 33.61% |
| Apr 3, 2011 | 26.61% |
| Dec 31, 2010 | 36.94% |
| Oct 3, 2010 | 39.98% |
| Jul 4, 2010 | 26.27% |
| Apr 4, 2010 | -40.21% |
| Dec 31, 2009 | 27.87% |
| Sep 27, 2009 | 33.04% |
| Jun 28, 2009 | 38.65% |
| Mar 29, 2009 | 26.63% |